• News


proACTINA exhibiting at BIO International Convention in San Diego/USA

Pro-ACTINA is proud to be exhibiting during BIO International Convention in San Diego, selected as one of the 15 European SMEs Instrument Ambassadors under the EASME Overseas Trade Fairs program aiming to support international commercialization of EU innovation. From 19-22 June 2017, pro-ACTINA will have the unique opportunity to gain first-hand experience of the US market and establish business contacts with local companies via the trade fair and business meetings.

The BIO International Convention (BIO) attracts 16,000 biotechnology and pharma leaders who come together for one week of intensive networking to discover new opportunities and promising partnerships.


[H2020 - SME Instrument – Overseas Trade Fairs Pavilion]

GLIOMARK 1 Phase II clinical study currently recruiting patients

GLIOMARK1 Phase II clinical study (EudraCT No: 2015-005573-21), as part clinical development of GLIOMARK project, is currently recruiting patients. The study is entitled: "Exploratory phase II study in patients after treatment of high grade brain tumors to assess the technical performance of Tc-99m tetrofosmin for differentiation of recurrence versus radiation necrosis"

Presentation of GLIOMARK

pro-Actina's CEO, Alexandros Strongilos, was invited to present the Gliomark project on Nov 3, 2015 in frame of a Horizon 2020 dedicated event organized by the Greek National Contact point.

Continue Reading

EC grants Orphan Drug Designation to proACTINA for tetrofosmin for diagnosis of Glioma

Athens, 26/10/2016

proACTINA SA, a research-driven and innovation-focused Small-Medium Enterprise in Athens-Greece, today announced that European Commission (EC) has granted Orphan Designation for tetrofosmin for the diagnosis of glioma, following a positive opinion by European Medicines Agency (EMA). The Decision was published in the Community Register of Orphan Medicinal Products and the product has received EU orphan designation number: EU/3/16/1764

For the full press release see: Orphan designation press release


  • 1
  • 2

Contact us

Address:20, Delfon Street
151 25 Marousi,
Email:This email address is being protected from spambots. You need JavaScript enabled to view it.